$The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies$
QR Code

The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 173; p. S21
Main Authors:	Zain, DR, Iyer, SP, Sica, RA, Ho, PJ, Hu, B, Prica, A, Weng, W-K, Kim, YH, Khodadoust, MS, Palomba, ML, Foss, FM, Tipton, K, Cullingford, EL, Horwitz, SM, Sharma, A
Format:	Journal Article
Language:	English
Published:	01-09-2022
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
ISSN:	0959-8049
DOI:	10.1016/S0959-8049(22)00591-3